%0 Journal Article
%T SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
%A García-Campelo R
%A Sullivan I
%A Arriola E
%A Insa A
%A Juan Vidal O
%A Cruz-Castellanos P
%A Morán T
%A Reguart N
%A Zugazagoitia J
%A Dómine M
%J Clin Transl Oncol
%V 25
%N 9
%D 2023 Sep 7
%M 37418123
%F 3.34
%R 10.1007/s12094-023-03216-3
%X Small-cell lung cancer (SCLC) is a highly aggressive malignancy comprising approximately 15% of lung cancers. Only one-third of patients are diagnosed at limited-stage (LS). Surgical resection can be curative in early stages, followed by platinum-etoposide adjuvant therapy, although only a minority of patients with SCLC qualify for surgery. Concurrent chemo-radiotherapy is the standard of care for LS-SCLC that is not surgically resectable, followed by prophylactic cranial irradiation (PCI) for patients without progression. For extensive-stage (ES)-SCLC, a combination of platinum and etoposide has historically been a mainstay of treatment. Recently, the efficacy of programmed death-ligand 1 inhibitors combined with chemotherapy has become the new front-line standard of care for ES-SCLC. Emerging knowledge regarding SCLC biology, including genomic characterization and molecular subtyping, and new treatment approaches will potentially lead to advances in SCLC patient care.